Avidity Biosciences (NASDAQ:RNA)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $63.22 (26.5% Upside)
About Avidity Biosciences
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Read More
Recent Analyst Ratings